These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38812276)

  • 1. Assessing heterogeneity in surrogacy using censored data.
    Parast L; Tian L; Cai T
    Stat Med; 2024 Jul; 43(17):3184-3209. PubMed ID: 38812276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating multiple surrogate markers with censored data.
    Parast L; Cai T; Tian L
    Biometrics; 2021 Dec; 77(4):1315-1327. PubMed ID: 32920821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using a surrogate marker for early testing of a treatment effect.
    Parast L; Cai T; Tian L
    Biometrics; 2019 Dec; 75(4):1253-1263. PubMed ID: 31009073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing for heterogeneity in the utility of a surrogate marker.
    Parast L; Cai T; Tian L
    Biometrics; 2023 Jun; 79(2):799-810. PubMed ID: 34874550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating surrogate marker information using censored data.
    Parast L; Cai T; Tian L
    Stat Med; 2017 May; 36(11):1767-1782. PubMed ID: 28088843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying the feasibility of shortening clinical trial duration using surrogate markers.
    Wang X; Cai T; Tian L; Bourgeois F; Parast L
    Stat Med; 2021 Dec; 40(28):6321-6343. PubMed ID: 34474500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using a surrogate with heterogeneous utility to test for a treatment effect.
    Parast L; Cai T; Tian L
    Stat Med; 2023 Jan; 42(1):68-88. PubMed ID: 36372072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust estimation of the proportion of treatment effect explained by surrogate marker information.
    Parast L; McDermott MM; Tian L
    Stat Med; 2016 May; 35(10):1637-53. PubMed ID: 26631934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the value of a censored surrogate outcome.
    Parast L; Tian L; Cai T
    Lifetime Data Anal; 2020 Apr; 26(2):245-265. PubMed ID: 30980316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flexible evaluation of surrogate markers with Bayesian model averaging.
    Duan Y; Parast L
    Stat Med; 2024 Feb; 43(4):774-792. PubMed ID: 38081586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robust approach to combining multiple markers to improve surrogacy.
    Wang X; Parast L; Han L; Tian L; Cai T
    Biometrics; 2023 Jun; 79(2):788-798. PubMed ID: 35426444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semiparametric inference for surrogate endpoints with bivariate censored data.
    Ghosh D
    Biometrics; 2008 Mar; 64(1):149-56. PubMed ID: 17651457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust methods to correct for measurement error when evaluating a surrogate marker.
    Parast L; Garcia TP; Prentice RL; Carroll RJ
    Biometrics; 2022 Mar; 78(1):9-23. PubMed ID: 33021738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity.
    Guo X; Bourgeois FT; Cai T
    Stat Methods Med Res; 2024 May; ():9622802241247719. PubMed ID: 38717356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of the proportion of treatment effect explained by a high-dimensional surrogate.
    Zhou RR; Zhao SD; Parast L
    Stat Med; 2022 May; 41(12):2227-2246. PubMed ID: 35189671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust nonparametric estimation of monotone regression functions with interval-censored observations.
    Zhang Y; Cheng G; Tu W
    Biometrics; 2016 Sep; 72(3):720-30. PubMed ID: 26757488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials.
    Dai JY; Hughes JP
    Biostatistics; 2012 Sep; 13(4):609-24. PubMed ID: 22394448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accommodating missingness when assessing surrogacy via principal stratification.
    Elliott MR; Li Y; Taylor JM
    Clin Trials; 2013; 10(3):363-77. PubMed ID: 23553326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple imputation for interval censored data with auxiliary variables.
    Hsu CH; Taylor JM; Murray S; Commenges D
    Stat Med; 2007 Feb; 26(4):769-81. PubMed ID: 16755528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.